Seres Therapeutics, Inc. (MCRB)

Healthcare · Pharmaceuticals · Price $4.91
Updated: Sep 1, 2026
Below Average Equity Returns — Healthcare
ROE of -25.88% — below the 10% floor Zyberno applies to Healthcare businesses.
ROE
-25.88%
Return on Equity
ROIC
-83.38%
Return on Invested Capital
ROA
-7.70%
Return on Assets
Debt/Equity
1.64x
Leverage Ratio
Book Value/Share
$3.56
Equity Per Share

🧮 MCRB ROE Calculation

ROE = Net Income / Shareholders' Equity
Net Income (TTM) $-9.6M
Shareholders' Equity $34.5M
Total Debt $56.6M
Debt-to-Equity Ratio 1.64x
ROE (Return on Equity) -25.88%

Understanding ROE

Return on Equity (ROE) measures how efficiently a company generates profits from shareholders' equity. For MCRB, the current ROE is -25.88%.

Why ROE Matters

Warren Buffett has called ROE one of his favorite metrics because it shows how well management uses shareholders' capital to generate returns. A company that consistently earns 15%+ ROE is typically a well-run business that creates value for shareholders.

High Leverage Warning

MCRB's debt-to-equity ratio of 1.64x is elevated. High ROE combined with high debt can be a red flag — the company may be using financial leverage to boost returns, which increases risk. Compare to ROIC for a more complete picture.

ROE Benchmarks

Excellent: >20%

Exceptional returns on equity. Often indicates strong competitive advantages. Common in capital-light businesses.

Good: 15-20%

Above-average ROE. Buffett often looks for companies in this range or higher.

Average: 10-15%

Typical for most companies. Returns are reasonable but not exceptional.

Below Average: <10%

May indicate poor capital allocation or challenging business conditions.

The DuPont Analysis

ROE can be decomposed into three components using DuPont analysis:

ROE = Net Margin × Asset Turnover × Equity Multiplier

This breakdown reveals whether high ROE comes from high profitability (good), efficient asset use (good), or high leverage (potentially risky).

ROE vs ROIC: Which is Better?

ROIC: -83.38% →

ROIC measures returns on ALL capital. It's more comprehensive and less affected by leverage. Often considered the better quality metric.

ROE: -25.88%

ROE only measures returns on equity. Can be inflated by high debt. If ROE >> ROIC, the company uses significant leverage.

Owner Earnings: $-42.4M →

Shows actual cash available to owners. Use alongside ROE and ROIC for complete analysis.

Net Income: $-9.6M →

The numerator in ROE. Understanding net income trends helps explain ROE changes over time.

What to Look For

📊 Full MCRB Stock Report

Intrinsic value, margin of safety, DCF valuation, and 250+ metrics.

🏆 MCRB ROIC

Compare ROE to ROIC — the more comprehensive measure of capital efficiency.

💹 MCRB P/E Ratio

Analyze valuation relative to earnings and understand market pricing.

👤 MCRB Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 MCRB Net Income

See the earnings that drive ROE calculations.

💵 MCRB Free Cash Flow

Actual cash generation after capital expenditures.

View Full MCRB Report Find More Quality Stocks
📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
🛡️
Margin of Safety
Valuation Gap
🎯
Expected Return
Projected Annual
Click any metric for full methodology and detailed analysis

Summary: MCRB Return on Equity

Seres Therapeutics, Inc. (MCRB) has a ROE of -25.88% — below the 10% floor Zyberno applies to healthcare companies where IP and regulatory advantages drive equity returns, indicating weak returns on shareholders' capital. Note: with a debt-to-equity of 1.64x, leverage is amplifying these returns — compare with ROIC (-83.38%) for a leverage-neutral view. For complete financial analysis, view the full MCRB stock report on Zyberno.

Frequently Asked Questions

What is MCRB's current ROE?

Seres Therapeutics, Inc.'s Return on Equity (ROE) is -25.88%, measured against the 20% excellent threshold Zyberno applies to Healthcare businesses. ROE measures the company's profitability relative to shareholders' equity.

Is MCRB's ROE good?

Seres Therapeutics, Inc. (MCRB) has a ROE of -25.88% — below the 10% floor Zyberno applies to healthcare companies where IP and regulatory advantages drive equity returns, indicating weak returns on shareholders' capital. Note: with a debt-to-equity of 1.64x, leverage is amplifying these returns — compare with ROIC (-83.38%) for a leverage-neutral view.

What is the difference between ROE and ROIC?

ROE measures returns on shareholder equity only, while ROIC measures returns on all invested capital (debt + equity). MCRB's ROE is -25.88% vs ROIC of -83.38%. ROE can be inflated by high debt, making ROIC often a more reliable quality metric.

Can high ROE be misleading?

Yes, high ROE can be misleading if achieved through high debt. MCRB's debt-to-equity ratio is 1.64x. Compare ROE to ROIC — if ROE is much higher than ROIC, the company uses significant leverage which adds risk.

📊 Full MCRB Stock Report

See MCRB's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

🏆 MCRB ROIC

Compare to Return on Invested Capital — the most comprehensive measure of capital efficiency.

💹 MCRB P/E Ratio

Analyze the price-to-earnings ratio and earnings yield as a valuation metric.

🎯 MCRB Earnings Surprise (SUE)

See whether MCRB is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

👤 MCRB Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 MCRB Net Income

See the bottom-line profit that drives return calculations.

📊 MCRB EPS

Earnings per share — net income on a per-share basis.

View Full MCRB Report Find More Quality Stocks
Scroll to Top